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Abstract
Cancer evolves through the accumulation of mutations, but the order in which mutations occur is poorly understood.
Inference of a temporal ordering on the level of genes is challenging because clinically and histologically identical tumors
often have few mutated genes in common. This heterogeneity may at least in part be due to mutations in different genes
having similar phenotypic effects by acting in the same functional pathway. We estimate the constraints on the order in
which alterations accumulate during cancer progression from cross-sectional mutation data using a probabilistic graphical
model termed Hidden Conjunctive Bayesian Network (H-CBN). The possible orders are analyzed on the level of genes and,
after mapping genes to functional pathways, also on the pathway level. We find stronger evidence for pathway order
constraints than for gene order constraints, indicating that temporal ordering results from selective pressure acting at the
pathway level. The accumulation of changes in core pathways differs among cancer types, yet a common feature is that
progression appears to begin with mutations in genes that regulate apoptosis pathways and to conclude with mutations in
genes involved in invasion pathways. H-CBN models provide a quantitative and intuitive model of tumorigenesis showing
that the genetic events can be linked to the phenotypic progression on the level of pathways.
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Introduction
Cancer progression is an evolutionary process that is driven by
mutations and clonal expansions in a cell population. Mutations in
cancer-associated genes can alter the behavior of a cell and result
in loss of cooperation and increased proliferation. Cells with
advantageous mutations eventually outgrow competing cells and
tumor development proceeds by successive clonal expansions. In
each clonal expansion, additional mutations are fixed in the
population. Cancer progression is therefore characterized by the
accumulation of these genetic changes [1,2,3].
Many oncogenes and tumor suppressor genes have been
identified that contribute to tumorigenesis when activated or
inactivated by mutation, respectively [4]. It is believed that cells
need to acquire certain key properties, including those sometimes
referred to as the hallmarks of cancer, to form a tumor [5,6].
Among these functional changes are avoidance of apoptosis,
angiogenesis, limitless replication potential, and invasion. Biolog-
ical functions are usually maintained by one or several groups of
genes that interact in functional pathways. Many signaling
pathways have been identified that play a key role in carcinogen-
esis [7] and recently a set of twelve core pathways was defined
[8,9,10].
Mathematical modeling of carcinogenesis has a long history,
starting with multi-stage models for the interpretation of cancer
incidence data [11,12,13]. Because cancer is an evolutionary
process, population genetics has provided useful models for
describing the dynamics of cancer cell populations [14,15,16,17].
The order in which genetic events tend to fixate in tumors is of
particular interest, because it might elucidate the critical events in
carcinogenesis and could even have therapeutic applications.
Tumors progress through a sequential series of genetic alterations,
but the order of these alterations can vary among tumors and
even among different compartments of the same tumor
[8,9,10,14,17,18,19,20]. This observation has prompted the
development of statistical methods that generalize the assumption
of a linear order in different ways [21,22,23,24,25,26]. Most of
these models have been applied to CGH data from various cancer
types but not yet to detailed cancer sequencing data.
Here, we use a class of graphical models, called Hidden
Conjunctive Bayesian Networks (H-CBNs) to describe the
progression of cancer at the level of genes and pathways
[27,28,29,30,31]. H-CBNs model the accumulation of alterations
under partial order constraints allowing for small deviations in the
actual data from the most likely progression model. The notion
behind the partial order assumption is that there exist constraints
on the sequence of genetic events characterizing the progression of
cancer development for some mutations, but not necessarily for all.
While in each tumor a specific linear series of mutations occurs,
progression may be different among tumors. The partial order is
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27136the set of order constraints, or relations, that holds for all tumors.
Here and in the following, we use the terms ‘order constraint’ and
‘relation’ synonymously. Inferring these partial order constraints
from experimental data is the main aim of this study.
The H-CBN model has three layers (Figure 1A): (1) Mutations
accumulate stochastically according to the partial order con-
straints. The rate at which each mutation arises and becomes
detectable in the population is described by a parameter li. (2) The
accumulation process is observed at the time of diagnosis, and the
individual genotype X of a tumor contains all alterations that have
occurred so far. (3) The observed mutation data Y, however, may
differ slightly from the true genotypes, because of missing
information or wrong interpretation. For example, intronic
mutations, epigenetic silencing, or genomic deletions may not be
detected, but have the same compromising effect on the gene.
Conversely, recorded mutations may be passenger mutations with
no functional consequences instead of drivers. These observation
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Figure 1. Schematic illustration of the H-CBN model and gene-to-pathway mapping. A. Partial order constraints, as denoted by arrows,
restrict the possible ordering in which mutations occur. In this example, mutation C arises only after A, and mutation D requires A and B to be
present. Mutations A and B can occur in any order. Because the order is only partial, the sequence of events can differ between tumors. The
accumulation of each mutation is described by a stochastic exponential waiting time process that corresponds to a clonal expansion. Each tumor
thus arises by a series of expansions that differs across tumors depending on the number of constraints. No constraints imply that all orderings are
possible; a linear (total) ordering corresponds to a single sequence of events for all cases. Tumors are examined at diagnosis and its genotype X
indicates all functionally altered genes that have accumulated until then (1: altered, 0: functional). The observed list of mutated genes Y, however, can
contain errors (red) due to incomplete data or wrong interpretation of the results. The most likely constraints and model parameters are estimated
from the data Y. B. Mapping of genotypes to core pathways. The list of observed tumor genotypes is transformed to a list of altered core pathways by
assuming that a pathway is altered if at least one member of that pathway is mutated. The order of core pathway alterations is then estimated using
the H-CBN model. The influence of the gene-to-pathway mapping on the estimated constraints is analyzed by permuting genes among tumors (red
arrows). To assess the stability of parameter estimates, bootstrap samples are drawn from the list of genotypes by sampling with replacement (green
arrows) and the inference algorithm is run on each.
doi:10.1371/journal.pone.0027136.g001
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constraints, and the error rate from the observed mutation data
using maximum likelihood (ML).
The data for the H-CBN model is, for each tumor, a list of
mutated genes or a list of altered pathways. Many mutations in
different genes can have the same, or a similar, effect if they act in
the same pathway [7,32]. We model this phenomenon by
analyzing twelve core pathways that were defined in ref. [8].
The core pathways are compiled from different annotation
databases and describe the central signaling pathways altered in
cancer. We assume that a core pathway is altered if any of its gene
members has a non-synonymous mutation. We then use the H-
CBN model to estimate in which order pathway alterations occur.
To assess the confidence of our estimates, subsets of the original
data are repeatedly drawn with replacement (bootstrapped), the
algorithm is applied to each, and the resulting output is analyzed
(Figure 1B). A high similarity among bootstrap results indicates
high confidence. A similar procedure is used to quantify the
contribution of the gene-to-pathway mapping to the ordering. The
mapping is expected to have an influence on the ordering, because
some pathways are larger than others, and genes can be part of
multiple pathways. To assess this effect, the genetic mutations are
permuted between tumors, thereby breaking all correlations and
leaving only those imposed by the mapping itself.
Results
Colorectal cancer
The prevalence screen published by Wood et al. [10] contains
data from 95 colorectal carcinoma samples in which the exons of
28 genes were sequenced. We considered non-synonymous
changes as driver mutations. Eight genes that were found to have
driver frequencies above 5% were chosen for estimating the gene-
based order constraints, namely APC (82.1% frequency), KRAS
(62.1%), TP53 (56.8%), PIK3CA (24.2%), FBXW7 (8.4%), TCF7L2
(7.4%), EPHA3 (5.3%), and EVC2 (5.3%) (Table S1A). The
estimated order constraints are displayed in Figure 2A. Mutations
in the APC gene appear to be initiating, followed by mutations in
KRAS, PIK3CA, and others. Interestingly, TP53 is mutated
independently of APC and KRAS, meaning that it could be
mutated before or after these mutations. APC mutations have the
highest accumulation rates (0.39 per year), in agreement with its
early driving role in colorectal carcinogenesis. KRAS and TP53
mutations accumulate at rates 0.12 and 0.06 per year, respectively.
With the exception of TCF7L2, the remaining mutations have
accumulation rates below 0.01 per year.
On average, 66% of the estimated order relations are also found
in bootstrap samples. The average frequencies for each order
constraint are displayed as edge labels in Figure 2A. The average
false positive rate (FPR) of bootstrapped edges relative to the
original estimate was 10.5% and the average false negative rate
(FNR) was 33.6% (Table 1).
After mapping colorectal cancer genes to core pathways, we
found that Apoptosis and Wnt/Notch signaling pathways always
occurred together. The same holds true for DNA damage control
and JNK signaling. This situation arises from the specific set of
genes predominantly altered in colorectal cancer, where multiple
core pathways are hit by a single mutation, viz. APC for the
Apoptosis/Wnt-Notch pathway and TP53 for the DNA damage/
JNK pathway (Table S1A). Because no further statistical inference
on the order of identically hit pathways is possible, they were
grouped together into two compound pathways (Figure 2A, right
panel). Colorectal cancer progression begins with mutations in the
Small GTPase pathway, followed by alterations of the Apoptosis/
Wnt-Notch and Homophilic cell adhesion pathways, often caused
by a single APC mutation. These alterations occur before
perturbations of genes in the KRAS and TGF-b signaling
pathways, as well as Control of G1/S phase. At later stages
DNA damage control and JNK are altered (through TP53).
Integrin signaling and subsequently Invasion are hit with the
lowest frequencies, indicating a role at later stages of progression,
but are modeled independently.
Under bootstrap re-sampling, the pathway FPR per relation is
9.8%, and the FNR is 32.7%, slightly smaller than the
corresponding gene-based values. Under permutations, where all
correlations of the genes are broken up, the FPR and FNR are
18.6% and 43.0%, respectively. Without the genetic correlations,
the FPR is almost twice as large as the bootstrap FPR, i.e., more
relations that were not in the original estimate were found. Also
the FNR is higher under permutations as compared to the
bootstraps, indicating that more of the original relations were
missed. Together, these results demonstrate that the structure of
the estimated model is sensitive to the particular combination of
the genetic mutations in each tumor, and not only a simple
consequence of the mapping.
To assess the impact of individual genes on the pathway-level
results, we computed the likelihood of the model if a gene is left out
from the analysis. Genes with a strong influence on the model fit
also have an effect on the likelihood (Figure S1A). Genes with a
strong impact were APC, KRAS, PIK3CA, and TP53, but also
TCFL7 and MMP2 showed a recognizable effect.
Pancreatic cancer
In the prevalence screen by Jones et al. [8], 22 genes in 90 cases
of pancreatic cancer were sequenced. The most frequently (.4%)
mutated genes were KRAS (98.9%), TP53 (84.4%), SMAD4
(25.6%), CDKN2A (24.4%), TGFBR2 (6.7%), MLL3 (5.6%), and
PXDN (4.4%).
The genetic order constraints are displayed in Figure 2B.
Mutations in KRAS initialize progression, followed by TP53,
CDKN2A, and MLL3. SMAD4 mutations occur independently of
those in KRAS. The average FPR and FNR were 15.1% and
42.7%, respectively (Table 1). The estimated accumulation rate of
KRAS mutations is very high, because the prevalence reaches
almost 100%. TP53 has the second highest rate of 0.34 per year,
underpinning its central role in cancer progression. The other
genes have lower accumulation rates between 0.15 (TGFBR2) and
6610
24 (MLL3) per year.
On the core pathway level, the Apoptosis, G1/S transition,
Hedgehog, and TGF-beta signaling pathways were altered in all
90 cases, and can thus be considered to occur at the earliest stages
(Table S1B). Conversely, the Invasion pathway was never affected
and may be assigned to the latest stage, if relevant at all.
The second stages of pancreatic cancer progression were found
to be Small GTPase-dependent signaling and KRAS signaling,
which arise independently. Both occur before a series of events,
consisting of DNA damage control, JNK, and Wnt/Notch
signaling. Integrin signaling is altered at late stages, after
Homophilic cell adhesion mutations.
The stability of the pathway constraints was again higher as
compared to the gene level. The FPR and FNR were 13.6% and
15.4%, respectively, under bootstrap sampling (Table 1). As in the
case of colorectal cancers, the pathway FPR is slightly smaller than
the genetic FPR (P=3 610
21), and FNR is significantly smaller for
pathways than for genes (P=1.6610
215). The FPR and FNR
under permutations were 8.5% and 51.4%. Thus, on average half
of the original relations is lost if the correlations of the genes are
erased, indicating that they cannot be explained by the gene-to-
The Order of Genetic and Pathway Alterations
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individual genes, KRAS and TP53, but also PXDN and MYH2
had an appreciable effect on the likelihood (Figure S1B).
Primary glioblastoma
Parsons et al. [9] sequenced 16 different genes in 83
glioblastoma cases. The most frequently (.5%) mutated genes
were TP53 (28.9%), PTEN (26.5%), EGFR (15.7%), NF1 (15.7%),
PIK3CA (9.6%), IDH1 (8.4%), PIK3R1 (7.2%), and RB1 (7.2%).
For this cancer type, the distribution of frequencies was more
uniform, with less pronounced ‘mountains’ (genes mutated at high
frequency), as compared to colorectal and pancreatic cancer. Of
the 83 glioblastoma cases, five were of the secondary type, which is
characterized by distinct genetics [9,33]. Consequently, the
secondary glioblastomas were found to have a significantly lower
likelihood in a model fitted only on the remaining cases (P,0.01,
cross-validation), indicating a worse fit for secondary glioblastomas
and diverging mutational pathways. We therefore restricted the
analysis to the remaining 78 primary glioblastomas. Of note, 16
out of these 78 cases contained mutations in none of the 16 genes
sequenced.
The first mutation occurs in TP53, parallel to which EGFR,
NF1, and PTEN mutate (Figure 2C). These alterations are followed
sequentially by mutations in PIK3CA, PIK3R1, and RB1. The
bootstrap stability of the relations was 11.6% (FPR) and 40.6%
(FNR), respectively (Table 1). In line with the low frequencies of
individual mutations, the estimated accumulation rates are all of
order 0.01 per year or lower, showing that the probability for a
specific gene alteration in this cancer type is low.
Despite the low frequencies of single gene mutations, the
Apoptosis and Small GTPase core pathways were altered in
79.2% of the samples and are hit first (Figure 1C). As in the case of
pancreatic cancers, no mutations were found in the Invasion
pathway consistent with a late role (Table S1C). Among other
early-mutated pathways are G1/S phase transition, Wnt/Notch
signaling, and KRAS signaling. These pathways occur before
mutations in DNA damage control and JNK signaling, as well as
in Homophilic cell adhesion and Integrin signaling which form an
independent branch.
The bootstrap stability of the relations was very high with a FPR
of 5.2% and a FNR of 10.9% and therefore more stable than that
determined on the gene level (P=3 610
220 and P=3 610
230,
respectively). This compares to a permutation stability of 11.4%
and 9.5%, respectively. Genes with a visible influence on the
model fit were TP53, RB1, PIK3CA, EGFR, and NF1 (Figure S1C).
All Cancer Types
We integrated all 268 cases to estimate a "global" model of
cancer progression on the pathway level. The resulting graphical
representation is shown in Figure 3, the complete gene-to-pathway
mapping can be found in Table S1D. The first event is Apoptosis
which occurs before TGF-b and KRAS signaling, as well as
Control of G1/S phase transition. Independently of this, Small
GTPase-dependent signaling, Hedgehog signaling, and Homo-
philic cell adhesion are hit. Late events occurring after these
changes are DNA damage control, Wnt/Notch signaling, and
JNK, but also Integrin signaling and Invasion at late stages.
The model fit is highly stable with average FPR=0.04 and
FNR=0.061 under bootstrapping. These values are significantly
lower under bootstrapping than under permutations (FPR=0.164,
P,6610
250, and FNR=0.289, P,3610
235, t-tests). The likeli-
hood of the model is largely influenced by mutations in TP53,
KRAS, NF1, PIK3R1, PIK3CA, PTEN, RB1, and APC (Figure S1D).
When comparing the topology of this model with the specific
cancer cases, one finds that for colorectal cancer, 14 of 31 relations
present in the colorectal poset are present in the unified model.
Moreover, the global model contains 5 of 11 relations of the
pancreatic poset and 5 out of 12 relations from the primary
glioblastoma model. The constraints found in the global model
may therefore be seen as the maximal subset of order constraints
that hold true for all cancer types. The unified model, however,
also contains constraints that could not be resolved in individual
cancer types, where some pathways were grouped together, or
have been either completely absent or universally present.
Discussion
In this work we have analyzed the order constraints under
which genetic alterations accumulate during cancer progression.
Figure 2. Most likely order constraints on the gene (left) and core pathway level (right) for colorectal cancer (A), pancreatic cancer
(B), and primary glioblastoma (C). Each edge in the graph denotes an order constraint on the accumulation of alterations. The two values
labeling each edge and separated by a slash denote relative frequencies of occurrence of the order constraint in permutation and bootstrap samples,
respectively. The estimated yearly accumulation rates are given below the gene name at each node of the graph. The color of a node reflects the
frequency of the alteration (dark green 100% to dark red 0%). Nodes labeled with white font have frequencies of exactly 100% or 0% and were not
considered for the statistical analysis.
doi:10.1371/journal.pone.0027136.g002
Table 1. Quality measures for the accuracy of estimated order constraints based on bootstrapping and permutations for genes
and core pathways. FPR= false positive rate, FNR= false negative rate.
Genes Core Pathways
Bootstrap Bootstrap Permutations
FPR FNR FPR FNR FPR FNR
Colorectal cancer 0.105 (0,0.286) 0.336 (0,0.662) 0.098 (0, 0.235) 0.327 (0.053,0.684) 0.219 (0.098,0.333) 0.551 (0.211,0.842)
Pancreatic cancer 0.151 (0,0.333) 0.427 (0.1,0.8) 0.136 (0,0.385) 0.154 (0,0.455) 0.085 (0,0.286) 0.519 (0.455,0.636)
Primary glioblastoma 0.152 (0,0.179) 0.427 (0.221,0.75) 0.052 (0,0.133) 0.109 (0,0.286) 0.114 (0.067,0.182) 0.095 (0,0.19)
All Cancer Types - - 0.04 (0,0.091) 0.061 (0,0.211) 0.164 (0.076,0.258) 0.289 (0.074,0.526)
Values in parentheses denote the confidence intervals defined by the 5% and 95% quantiles.
doi:10.1371/journal.pone.0027136.t001
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cancer as well as glioblastomas on the level of individual genes,
and also on the phenotype level of functional pathways. The
analysis was based on a probabilistic graphical model, termed H-
CBN, which was used to estimate the most likely set of order
constraints, the rate at which each individual alteration occurs,
and the observation error rate. We found differences in the
ordering across cancer types and generally stronger evidence for
order constraints on the pathway level than on the gene level.
In the gene-level model of colorectal cancer progression, APC
has an initializing role, followed by mutations in KRAS. This
resembles the progression proposed in an early study of this cancer
type [19]. It appears, however, that the role of TP53 mutations
might be more flexible. In the original model, TP53 mutations
occurred after KRAS mutations. The late occurrence of p53
mutations has been experimentally observed since that time [34]
and the most likely mutational pathway in our model also begins
APC R KRAS R TP53 R PIK3CA, followed by other mutations.
However, the model we obtained allows for several other
sequences of mutations and, on a population level, we estimate
TP53 mutations to occur independently of all other mutations
(P=0.01 in bootstrap samples), including APC and KRAS. Whether
this difference reflects a limitation of the model, lack of statistical
power, a defect in the experimental data, or our understanding of
the pathways through which p53 acts, remains to be determined.
For the majority of genes the estimated accumulation rates of
individual mutations li were of order 0.01 to 0.001 per year, but
some mutations in colorectal carcinoma and pancreatic cancer
have higher values of order one per year. Among those were TP53,
KRAS, and for colorectal cancer, also APC. The inferred
accumulation rates can be related to the fitness surplus a mutation
contributes in a clonal expansion model. Under the assumption of
an identical mutation rate per gene, an accumulation rate of 1 per
year corresponds approximately to a fitness surplus of 2.6%
(Methods Section). Therefore the high accumulation rates of
TP53, KRAS, and APC can be explained by a fitness effect on the
order of a few percent, compared to other mutations with lower
fitness gains of order 10
23 or 10
24. Thus, these critical genes,
which also form the mountains in the mutation landscape
[8,10,20], may act as ‘superdrivers’ that provide a higher fitness
gain than other genes.
Interestingly, this effect was not as pronounced in glioblastomas,
where the mutation spectrum was also found to be flatter and
fewer mutations were found in each tumor. One possible
explanation for the absence of mountains in glioblastoma could
be that the cellular context limits the possible fitness gain by single
mutations, leading to a flatter mutation landscape. It may also be
that other lesions that were not assessed in our data sets drive
disease progression. It is striking, however, that despite the low
levels of individual gene mutations and the absence of a clear
genetic pattern there exist a robust signature of progression on the
pathway level. Possibly, for glioblastoma larger parts of the
pathways are active and vulnerable to mutations than in other
cancer types that only permit mutations in a subset of genes with
high mutation prevalence.
In pancreatic cancer, KRAS mutations are present in virtually all
tumors. In this case, the estimated accumulation rate represents an
almost instantaneous appearance of KRAS mutations at the onset
of disease because only one case without KRAS is observed. It
appears that the progression is initiated by KRAS mutations,
followed by additional mutations in CDKN2A, SMAD4, TP53, and
MLL3 in a second stage and PXDN and TGFBR2 in a third stage.
Notably, the three stages are consistent with a three rate-limiting
steps model fitted to age-incidence data [35].
The average frequency at which any pathway was altered in all
samples was 70.0% in colorectal carcinoma, 72.0% in pancreatic
cancer, and 67.7% in glioblastoma. This relatively high frequency
probably reflects that the analyzed samples were all late-stage
carcinomas. This finding is in contrast to the fact that, on the gene
level, typically only a few genes have prevalence higher than 50%.
Due to the joint action of multiple genes in different pathways,
however, the frequency of pathway alterations can be high. A
striking example is glioblastoma, were no gene has a mutation
frequency higher than 35.8% (TP53), but the Apoptosis and Small
GTPase pathways contain mutations in 79.2% of the samples
analyzed.
The global model contains in total 19 order constraints among
the 12 core pathways, which restrict the number of possible
sequences in which the pathway alterations arise in a particular
tumor from 12!=479,001,600 to 356,640. Of these, the most
likely sequence given the order constraints and the individual
accumulation rates is: Apoptosis R TGF-b signaling R Small
GTPase-dependent signaling (other than KRAS) R Wnt/Notch
signaling R Control of G1/S phase transition R KRAS signaling
R Hedghehog signaling R DNA damage control R JNK R
Homophilic cell adhesion R Integrin signaling R Invasion.
Mutations in the Apoptosis core pathway are early events in all
cancer types evaluated here. For colorectal carcinogenesis, it is
thought that APC mutations initiate carcinogenesis by compro-
mising apoptosis in colonic endothelial cells resulting in the
creation of adenomatous polypes [36]. In these cell pools,
additional mutations accumulate and drive malignancy [37].
Figure 3. Global pathway progression model for all three cancer types. Each edge denotes an order constraint. The two numbers at
each edge are the frequencies at which the given relation is observed under permutations of the genes and bootstrapping of the data, respectively.
Colors denote the relative frequencies at which each pathway is hit by at least one mutation.
doi:10.1371/journal.pone.0027136.g003
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27136Our analysis shows that similar mechanisms could also act in
pancreatic cancer and primary glioblastoma. The reason why the
loss of apoptotic control is a critical step for initiating cancer can
be understood from an evolutionary argument: The larger the
population, the higher the number of cells at risk of acquiring
additional mutations, and the higher the probability that cells with
increased proliferation reach fixation [14]. In healthy organs,
tissue organization reduces the number of cells at risk, for example,
by organizing the tissue into stem cell niches such that only
mutations in the stem cells can reach fixation [2]. This
organization, however, breaks down if cells fail to undergo
apoptosis and accumulate in an uncontrolled manner. In contrast
to the findings for the Apoptosis pathway, mutations in the
Invasion pathway are rare and occur late. This finding also agrees
with our current understanding of carcinogenesis, wherein the
capacity to invade other tissues and to metastasize is the last and
often lethal step.
Despite the success of this model to recapitulate some critical
aspects of neoplasia, there are several limitations. One is that our
current annotation of signaling pathways is far from complete and
many concurring definitions exist. We have therefore used a
curated compilation of ‘core pathways’ from different sources to
avoid a bias to a particular database. Yet the underlying data is
often obtained from other species and cell types, whereas it is
becoming increasingly clear that gene networks operate in a tissue-
and species-specific fashion. It is striking, however, that despite
these limitations in pathway annotations, our model is capable of
inferring an ordering of alterations that is consistent with our
current understanding of disease progression. As our knowledge of
pathways improves through advanced systems biology approaches,
we can expect our model to be more accurate and informative.
The robustness of the model fits was determined by boot-
strapping, with estimated per-relation error rates of order 10%. In
the future, the stability can be expected to improve further using
larger cohorts from current cancer genome projects that aim to
identify alterations in all genes in thousands of cancers. We
observed that the stability of the genetic model was generally lower
than that of the pathways. This may be attributed to the fact that,
with a few exceptions such as TP53 and KRAS, the mutation
frequencies are very low. There is thus only weak evidence for
specific order constraints on the accumulation of genetic
mutations. This limitation should be at least partially resolved
through the analysis of additional tumors, which will engender
more confidence in the causality of mutations that occur at
relatively low frequencies.
In our analysis, we considered a gene to be compromised in its
function if there was a non-synonymous exonic mutation. While
this may be true for most genes, there exist situations where this
simple interpretation fails, or where additional lesions, such as
genomic losses or epigenetic silencing, are required to inactivate a
gene. These effects were subsumed in the error rate e; larger data
sets and integration of different data types can be expected to yield
lower error rates and also better estimates of the order constraints.
In summary, the H-CBN model presents a framework for
estimating the order constraints under which alterations in tumors
accumulate over time. While there exist subtle differences in the
order in which core pathways are altered in different cancer types,
a common theme is that apoptosis is affected first, while invasion is
affected at a late stage. The pathway H-CBN model may also be
used to help define precise genetics-based progression measures
with prognostic impact [25]. Moreover, the explicit nature of the
error process allows for imputing the true genotypes from the data.
This principle was shown to yield more accurate survival
predictors for cytogenetic data for renal cell carcinomas [30].
The exomes of thousands of tumors will be sequenced in the next
several years. We anticipate that the approach described here will
be very useful for the analysis of these data and the statistical
power gained from these large cohorts will further increase the
accuracy of the model’s predictions.
Materials and Methods
Hidden conjunctive Bayesian network model
We use the Hidden Conjunctive Bayesian Network (H-CBN)
model defined in ref. [30]. In this model, alterations accumulate
with respect to partial order constraints and the observed data may
also contain observation errors. For example, errors can occur if a
detected mutation is not functional, or if pathway membership is
not correctly assigned. Genetic alterations occur according to
exponential waiting time processes that are subject to partial order
constraints [29]. The waiting time for mutation i is defined as




Exp, and the maximum is over all mutations j that are immediate
predecessors of mutation i according to a fixed partial order P.T h e
definition implies that all predecessor (or parent) mutations j [ pa(i)
must be present before mutation i can occur.
The result of the waiting time processes is observed at the time of
diagnosis, denoted Ts, and themutationsthathaveoccurred priorto
diagnosis constitute the genotype of the tumor, X=(X1,… ,Xn),
where Xi=1ifTi,Ts indicates the occurrence of mutation i,a n d
Xi=0 otherwise. Because the exact time of diagnosis with respect to
the onset of tumorigenesis is unknown and likely to vary across
patients, Ts is modeled as an independent, exponentially distributed
waiting time with parameter ls=1/(20 years). This choice was
made to reflect the approximate time from the unknown onset of
disease to diagnosis, which was estimated to be 10–20 years [35,37].




     
ð2Þ
This probability can be computed efficiently by summing over all
possible paths starting with zero mutations and leading to the
genotype X under the constraints of the poset [29].
With probability e the observation Yi of mutation Xi is incorrect.




where d(X, Y) is the Hamming distance counting the number of
differences between X and Y. The unobserved true genotypes X
and the waiting times T=(T1,… ,Tn) are hidden variables in the
Bayesian network defined by T, X, and Y. The resulting marginal




Pr(YjX,e)P r ( Xjl,P) ð4Þ
The symbol G denotes the lattice of genotypes compatible with the
partial order P. The network parameters e, l=(l1,… ,ln), and P
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involves an expectation-maximization algorithm. The most likely
poset, denoted by ^ P P, is found by simulated annealing [30]. A
schematic overview of the H-CBN is given in Figure 1A.
Genetic data and core pathways
Genetic data was obtained from the publicly available
prevalence screens of refs. [8,9,10] in which the exons of 20 genes
mutated at high frequency in each cancer case were screened for
100 patients. We considered a gene to be mutated if it contained at
least one non-synonymous base substitution or indel. For
estimating the genetic H-CBN model, only genes with mutation
frequencies greater than 5% were selected for each cancer type.
This pre-selection step was done for the genetic analysis because
simulations show that the statistical power to learn relations for
very rare mutations is low [30].
To assess progression on the pathway level, the complete
genotypes with all recorded mutations were mapped to the set of
twelve core pathways defined in ref. [8]. A given core pathway is
assumed to be altered if at least one of its members is mutated.
Some genes are members of multiple core pathways. If such a gene
is mutated, all pathways in which the gene is active are considered
to be affected. The process of mapping is illustrated in Figure 1B.
The H-CBN software, and additional code and data for analyzing
the gene-to-pathway mapping can be downloaded from our
website http://www.cbg.ethz.ch/software/ct-cbn.
Bootstrap and permutation analysis
To assess the robustness of the estimated order constraints, we
performed a bootstrap analysis. For each cancer type, 100 bootstrap
samples were generated and the ML posets were estimated as
described above. For each possible relation, the average occurrence
in the ML poset was computed. Values close to one or zero indicate
a high level of confidence for the presence or absence, respectively,
of this relation. As overall measures of the stability of posets we
consider the estimated false positive rate (FPR) and false negative
rate (FNR) over all poset relations in the bootstrap posets ^ ^ P P ^ P P relative
to the ML poset ^ P P obtained from the original dataset:
FPR~




# of relations in ^ P P but not in ^ ^ P P ^ P P
# of relation in ^ P P
ð6Þ
where r0=n(n21)/2 is the maximum number of relations
(constraints) that can be found, which is the case for the linear
poset. Here, the number of relations includes all direct constraints,
termed "cover relations", and indirect constraints that can be
derived from the cover relations. For example, the poset A R B R
C, has two cover relations, which imply the indirect relation A R
C, because C also comes after A, giving in total r0=3 relations.
The false positive rate is maximal, FPR=1, if the bootstrap
estimate ^ ^ P P ^ P P is linear, and all relations are different from those
defined in ^ P P (e.g., by a reversal of the ordering, or if ^ P P has no
relations. If, on the contrary, all boostrapped relations are
contained in the original poset, it follows that FPR=0. The false
negative rate FNR measures the relative number of relations in ^ P P
that are missed by ^ ^ P P ^ P P. From the collection of bootstrap samples, the
average FPR and FNR are computed.
To assess whether the estimated poset structures were merely a
consequence of the pathway mappings and the marginal
frequencies of the mutations, rather than an effect of their specific
co-occurrence, we shuffled, for each gene, the occurrence of the
mutations in order to break all correlations between mutations and
again estimated the ML posets. The permutations hold the
population frequencies of each mutation constant and generate the
distribution of posets under the null hypothesis of independently
occurring mutations. This procedure was repeated for 100
permutations and the frequencies of each relation in the ML
poset were computed. We then computed FPR and FNR for the
ML poset ^ P P as in Eq. (6).
The differences between bootstrapping and gene-wise permut-
ing are illustrated in Figure 1B. Bootstrapping is done on the set of
tumors and the composition of each genotype remains intact. By
contrast, gene-wise permutations break the correlation between
genes, and therefore allow for assessing to which extent the
observed dependencies on the pathway level stem from the
definition of pathway membership alone.
Relation to population genetics models
The average waiting time ti for mutation i, given that all the
necessary predecessors have occurred, is 1/li. This waiting time may
be interpreted asthe time untilthe mutation has occurred and reached
fixation in the population. It has been shown recently that the
expected waiting time between two successive clonal expansions in a
Wright-Fisher model is approximately ti~log(si=m)= 2 si logN ðÞ
[14,31]. Here, si is the fitness of the clone, m the mutation rate, and N
the population size. For logsivvlogm, the approximate fitness





The average population size is assumed to be N=10
6 cells, and the
mutation rate m=10
27 per gene. The fitness depends only
logarithmically on these two quantities, so even a change by an
order of magnitude has only a moderate effect. Under these
conditions, and for one cell generation per day, one has the relation
si&0:026 li, that is, fitness is approximately one fortieth of the
yearly accumulation rate.
Supporting Information
Figure S1 Log-likelihood of the core pathway model after
exclusionofindividualgenes forthe three cancertypes (A–
C) and the global model including all cancer types (D). The
solid line is the cumulative distribution function (CDF) of the log-
likelihood under bootstrapping. Genes (black dots) with a strong
influence on the likelihood are found in the tails of the CDF.
(EPS)
Table S1 Gene-to-pathway mapping and alteration
frequencies for all colorectal cancer (A), pancreatic
cancer (B), primary glioblastoma (D), and the combined
data for all three tumor types (D).
(XLSX)
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